- Home
- ACRS vs SAVA Comparison
ACRS vs SAVA Comparison
Compare ACRS & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- SAVA
- Stock Information
- Founded
- ACRS 2012
- SAVA 1998
- Country
- ACRS United States
- SAVA United States
- Employees
- ACRS N/A
- SAVA N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- ACRS Health Care
- SAVA Health Care
- Exchange
- ACRS Nasdaq
- SAVA Nasdaq
- Market Cap
- ACRS 132.0M
- SAVA 132.3M
- IPO Year
- ACRS 2015
- SAVA N/A
- Fundamental
- Price
- ACRS $2.60
- SAVA $2.62
- Analyst Decision
- ACRS Strong Buy
- SAVA Buy
- Analyst Count
- ACRS 5
- SAVA 3
- Target Price
- ACRS $11.00
- SAVA $111.50
- AVG Volume (30 Days)
- ACRS 956.3K
- SAVA 3.3M
- Earning Date
- ACRS 02-25-2025
- SAVA 02-26-2025
- Dividend Yield
- ACRS N/A
- SAVA N/A
- EPS Growth
- ACRS N/A
- SAVA N/A
- EPS
- ACRS N/A
- SAVA N/A
- Revenue
- ACRS $27,079,000.00
- SAVA N/A
- Revenue This Year
- ACRS N/A
- SAVA N/A
- Revenue Next Year
- ACRS N/A
- SAVA N/A
- P/E Ratio
- ACRS N/A
- SAVA N/A
- Revenue Growth
- ACRS 26.35
- SAVA N/A
- 52 Week Low
- ACRS $0.95
- SAVA $2.23
- 52 Week High
- ACRS $5.17
- SAVA $42.20
- Technical
- Relative Strength Index (RSI)
- ACRS 44.33
- SAVA 29.65
- Support Level
- ACRS $2.31
- SAVA $2.65
- Resistance Level
- ACRS $2.64
- SAVA $2.78
- Average True Range (ATR)
- ACRS 0.16
- SAVA 0.22
- MACD
- ACRS 0.02
- SAVA 0.52
- Stochastic Oscillator
- ACRS 58.76
- SAVA 38.46
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.